EXAS - Exact Sciences Corporation
| Previous Close | 97.74 |
| Open | 96.83 |
| Bid | 96.27 x 1200 |
| Ask | 96.78 x 800 |
| Day's Range | 95.68 - 98.33 |
| 52 Week Range | 47.78 - 105.28 |
| Volume | 1,336,721 |
| Avg. Volume | 1,894,006 |
| Market Cap | 12.422B |
| Beta (3Y Monthly) | 2.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.77 |
| Earnings Date | Jul 30, 2019 - Aug 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 114.00 |
- PR Newswire•2 days ago
Exact Sciences Presents New Data Reinforcing Performance of Cologuard®
SAN DIEGO, May 17, 2019 /PRNewswire/ -- New research from Exact Sciences and Mayo Clinic demonstrates the ability of Cologuard to both screen large patient populations and consistently help detect colorectal cancers and pre-cancers regardless of lesion location. The findings, presented at Digestive Disease Week (DDW) 2019, reinforce the role of Cologuard in improving colorectal cancer screening rates and patient outcomes. Despite recent efforts to positively impact colorectal cancer screening rates in the US, one-in-three Americans ages 50 to 75 are not up to date with recommended screening.i New research suggests the Cologuard test can help screen more people.
- American City Business Journals•3 days ago
Exact Sciences returning $61K in WEDC tax credits because jobs were created outside Wisconsin: AP
Exact Sciences Corp., the Madison-based maker of the Cologuard take-home colon cancer test and one of the largest public companies in Wisconsin, is reportedly returning $61,000 it received from the Wisconsin Economic Development Corp. because a certain number of jobs the money was intended for were created outside of Wisconsin. In 2015, Exact Sciences was approved by the WEDC to receive up to $9 million in tax credits if it added at least 750 jobs and made a capital investment of $26 million by 2020. Under the agreement, Exact Sciences would receive the WEDC tax incentives by investing in capital expenditures in Wisconsin and creating 758 new full-time positions – with an average wage of $24.47 per hour – in the state by Dec. 31, 2020.
- Motley Fool•4 days ago
3 Top Healthcare Stocks to Buy in May
These look like great picks to buy in May before you go away.
- Markit•5 days ago
See what the IHS Markit Score report has to say about Exact Sciences Corp.
Exact Sciences Corp NASDAQ:EXASView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low and declining Bearish sentimentShort interest | PositiveShort interest is low for EXAS with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on May 10. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding EXAS totaled $400 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Motley Fool•8 days ago
Guardant Health Takes Aim at Exact Sciences
A new study is planned that could someday reshape colon cancer screenings.
- Motley Fool•10 days ago
Why Exact Sciences Shrugged Off the Moody Market in April
Exact Sciences stock hit an all-time high last month, despite a sour market for biotech stocks.
- MarketWatch•17 days ago
The stock market’s reaction to this one word from the Fed’s Powell shows investors should be careful
Sometimes the U.S. stock market sends a clear, unambiguous message. The message the stock market sent during Federal Reserve Chairman Jerome Powell’s press conference Wednesday says that the market is vulnerable. • The chart shows that the stock market rose immediately after the Fed decision was announced.
- Thomson Reuters StreetEvents•17 days ago
Edited Transcript of EXAS earnings conference call or presentation 30-Apr-19 9:00pm GMT
Q1 2019 Exact Sciences Corp Earnings Call
Motley Fool•18 days agoExact Sciences Corp (EXAS) Q1 2019 Earnings Call Transcript
EXAS earnings call for the period ending March 31, 2019.
- PR Newswire•18 days ago
Exact Sciences to participate in May investor conferences
MADISON, Wis., May 1, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conferences and invited investors to participate by webcast. The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer.
- Motley Fool•18 days ago
What You'll Want to Know About Exact Sciences' Q1 Earnings
The maker of the Cologuard colorectal cancer screening test reported tremendous revenue growth -- but a worsening bottom line.
- Associated Press•19 days ago
Exact Sciences: 1Q Earnings Snapshot
The Madison, Wisconsin-based company said it had a loss of 66 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was ...
- American City Business Journals•19 days ago
Exact Sciences reports 79% jump in Cologuard test volume, first-quarter revenue
The company raised its guidance for its fiscal 2019, anticipating revenues between $725 million and $740 million.
- PR Newswire•19 days ago
First-quarter revenue and Cologuard test volume increased 79 percent to $162 million and 334,000, respectively
- Estimated Cologuard market share increased to 4.6 percent during the first quarter - Nearly 14,000 health care providers ordered their initial Cologuard test during the first quarter, and more than 160,000 ...
- ACCESSWIRE•19 days ago
EXACT Sciences Corp. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / April 30, 2019 / EXACT Sciences Corp. (NASDAQ: EXAS ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on April 30, 2019 at 5:00 PM ...
- Zacks•19 days ago
The 5 Hottest Earnings Charts This Week
These 5 stocks have had big rallies in 2019. Are they too hot to handle?
- Reuters•25 days ago
Older workers helped fuel recent U.S. growth. Can it last?
As a record-breaking economic expansion nears the decade mark, people like Marty Groth may determine whether it is forced into a lower gear. Not long ago, the 60-year-old Groth found himself out of a job and considered retiring on a pension built over a career of maintaining computer servers and printers. Instead, he returned to school to update his computer skills and will soon join a Wisconsin labour force that is decidedly short of workers.
- Zacks•26 days ago
Earnings Preview: Exact Sciences (EXAS) Q1 Earnings Expected to Decline
Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool•27 days ago
Exact Sciences Is Near an All-Time High: Here's Why It Could Go Even Higher
Here's why Cologuard's popularity will continue to climb for a long time.
- Zacks•27 days ago
Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store?
During Exact Sciences' (EXAS) first-quarter 2019 conference call, investor focus will be on the growth rate in the company's non-invasive screening test volume for colorectal cancer, Cologuard.
- InvestorPlace•27 days ago
7 Strong Buy Stocks the Street Loves
[Editor's note: This story was previously published in March 2019. It has since been updated and republished.]Which top stocks are Wall Street analysts the most bullish on? I mean stocks with no "hold" or "sell" ratings and a pure "strong buy" analyst consensus. These are the strong buy stocks that make the most compelling investing opportunities and are definitely worth keeping a close eye on.Using TipRanks powerful stock screener, I set out to pinpoint seven stocks that command the unanimous support of the Street. You can customize the screener settings to match your investment strategy. In this case, I selected filters for stocks of all market cap size with a "strong buy" consensus from analysts and best-performing analysts alike. These are the top analysts with the highest success rate and average return.InvestorPlace - Stock Market News, Stock Advice & Trading TipsHere I specifically select stocks with big upside potential from the current share price. This is based on the upside potential from the current share price to the average analyst price target. * 5 Dividend Stocks Perfect for Retirees Now let's delve into these seven top stocks to buy now:Source: Shutterstock Strong Buy Stocks: Exact Sciences (EXAS)Exact Sciences Corporation (NASDAQ:EXAS) has just received five back-to-back buy ratings from the Street. These "buys" flooded in following stellar Q4 earnings results. EXAS delivered a solid Q4 revenue beat and raised its 2019 revenue guidance to $710 million-$730 million, above its prior $700 million estimate. As it prepares to release its Q1 numbers April 30, those numbers still look achievable.Plus the future looks bright for sales for its Cologuard DNA test for colon cancer."EXAS is one of our top picks for 2019, and we reiterate our "buy" rating and our $100 PT," said five-star Canaccord Genuity analyst Mark Massaro. "Exact continues to execute at a high level and isn't afraid to make big investments to hit its ambitious goal of achieving $6 billion of revenue for Cologuard over time."That would give the company over 40% market share for its revolutionary screening product, first launched back in 2014.According to Massaro, even the new revenue guidance is beatable, writing "we see a path to upside to our raised estimates." A similar message comes from Baird's Catherine Ramsey. She writes: "We continue to see the potential for upside… and EXAS remains one of our top ideas."The average analyst price target right now stands at $104. Bear in mind shares have surged 45% year-to-date. Want to learn more about Exact Sciences? Get the free EXAS Stock Research Report.Source: Shutterstock OpenText (OTEX)Canadian cloud computing stock Open Text Corp (NASDAQ:OTEX) develops and sells enterprise information management (EIM) software. Essentially, this helps organizations safely manage and share business information.Since the company's inception in 1991, OpenText has deployed around $6 billion capital on acquisitions. Using these acquisitions, OTEX can cement its position as a leader in the EIM space."Our strategy is total growth," said CEO Mark Barrenechea said, "where M&A will continue to be our largest growth driver, augmented with organic growth." So far this strategy appears to be paying off. * 10 S&P 500 Stocks to Weather the Earnings Storm That level of optimism still is on Open Text's side as it prepares its May 1 report report on third-quarter earnings."We believe OpenText is likely to continue to create shareholder value through its acquisition strategy," RBC analyst Paul Treiber said following the encouraging Q2 numbers,Overall, five analysts have published recent bullish calls on the stock. That's with a $46.75 average price target -- 23% upside potential from the current share price. Shares are up 17% year-to-date. Get the OTEX Stock Research Report.Source: Shutterstock Moderna (MRNA)Moderna (NASDAQ:MRNA) is a pioneer in a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching. No less than eight analysts have published recent buy ratings on the stock.Right now the company just reported positive results from an ongoing phase Ib trial. This is for mRNA-1653, an mRNA-based vaccine for the treatment of human metapneumovirus (HMPV) and parainfluenza virus (PIV3)."The interim phase I data announced today support our outlook for this experimental product and support advancing studies in the pediatric population" said Oppenheimer's Leah R Cann.The mRNA-1653 program is one of Moderna's 21 most current and importantly, one of its 13 focus programs.She points out that currently there are no approved vaccines to prevent hMPV or PIV3 infections, and estimates that worldwide mRNA-1653 sales could reach $1.44 billion by 2030. That's with a predicted launch date of 2024.With a $27 price target, Cann sees upside potential of 19% for the coming months. Shares are currently surging more than 45% in 2019. Get the MRNA Stock Research Report.Source: Flash.pro via Flickr (modified) Nexstar Media (NXST)Following its completion of the Media General acquisition, Nexstar Media Group (NASDAQ:NXST) owns 171 television stations. As the largest TV station operator in the U.S. reaching nearly 39% of households, Nexstar Media Group is a stock worth watching.Analysts certainly seem to think so. Nexstar has received six recent buy calls from the Street. Most notably, Evercore ISI's David Joyce upgraded NXST from "hold" to "buy" back in December. As a result, Nextar Media stock now scores unanimous support.Crucially, the company is on the verge of a fresh acquisition. It has agreed a $6.4 billion deal to buy Tribune's ABC, CBS, FOX, and NBC stations. Tribune shareholders recently approved the deal. What's more, to help avoid any anti-trust issues, Nexstar has announced that it would sell 14 stations. * 7 Marijuana Companies: Which Pot Stocks Should You Buy? "We assign Nexstar an Outperform rating and a $112 price target. We believe that the Tribune acquisition should create significant value for shareholders," top RBC Capital analyst Leo Kulp tells investors.He ramped up his price target from $96 to $112 (23% upside potential) adding, "We see limited risk around regulatory approvals…We expect the FCF yield to moderate as the company completes the milestones to closing the deal and de-levers post-closing." Get the NXST Stock Research Report.Source: Ace Via on Flickr Boyd Gaming (BYD)Shares in Boyd Gaming Corp (NYSE:BYD) have exploded by 11% in just five days. That's thanks to a pretty exceptional earnings report for the Paradise, Nevada-based casino company."BYD's 4Q18 operating results were nothing short of sensational," said five-star Stifel Nicolaus analyst Steven Wieczynski. "As we get late into EPS season, we believe we have seen the best print to date, with BYD's strong 4Q18 results tonight, an exclamation point on a strong 2018, with guidance above expectations serving as the cherry on top."With widespread growth throughout the business, BYD EBITDAR came in at $208.6mm, easily surpassing the estimated $197.1 million. Meanwhile 2019 EBITDAR guidance was established at a healthy $885 million-910 million, the midpoint of which was above Consensus forecasts ahead of the print ($888 million)."Post the strong 4Q18 results and with, we believe BYD is well positioned to continue to show healthy and steady same-store growth, while continuing to integrate its accretive acquisitions from the 2H18," said Deutsche Bank's Carlo Santarelli.That's with a "very compelling" current valuation to boot. With a "strong buy" analyst consensus, BYD boasts five recent buy ratings and a $37.80 average price target (22% upside potential). Get the BYD Stock Research Report.Source: Shutterstock LivePerson (LPSN)As the name suggests, LivePerson (NASDAQ:LPSN) provides online real-time assistance and expert advice. The cloud-based chat company has just hit all-time highs following its strongest revenue growth in three years. For the third time in a row, LPSN reported 14% quarterly revenue growth. Shares are now up 50% year-to-date.Even if the company can't keep up the pace when it reports earnings May 2, it still is a keeper.Going forward, analysts are firmly bullish about LivePerson's outlook. Seven analysts have published recent buy ratings on the stock, including (five-star Oppenheimer analyst Koji Ikeda. * 7 AI Stocks to Watch with Strong Long-Term Narratives "We believe LivePerson is well positioned to take share in a large B2C messaging opportunity that is disrupting the contact center" writes Ikeda. "Organizations around the world are under pressure to rethink and retool legacy technologies with next-generation customer engagement applications, like LivePerson, to better engage, retain, and generate revenue from the end-consumer" the analyst explains.He believes that over time, good execution in quarterly results and improving business fundamentals should narrow the valuation gap between LPSN and the SaaS Industry average. That makes it a great strong buy stock. Get the LPSN Stock Research Report.Source: Shutterstock Cubic Corp (CUB)Despite Brexit concerns and increasing volatility, Growth remains par for the course for Irish defense contractor Cubic Corp (NYSE:CUB).The company has three key business divisions. For investors, it is the company's flagship Cubic Transportation Systems unit that is worth keeping an eye on. According to the company, this is the division responsible for "automated fare payment, traffic management and enforcement solutions."Indeed, transport systems revenue was up 24% year over year, according to CUB's most recent earnings report. Consequently, Citigroup's Jonathan Raviv cited recent wins- especially in transport- as behind his bullish take on the stock.Meanwhile, Drexel Hamilton's David Williams writes: "We remain positive on CUB and expect further acquisitions to supplement top and bottom-line growth, which is likely to drive short term upside to expectations, and provide a strong long-term growth trajectory."As such, the analyst reiterates his "buy" rating and $85 price target (38% upside potential) on this strong buy stock. Six analysts give the stock a buy rating, while their average price target works out at $76.80. Get the CUB Stock Research Report.TipRanks.com offers exclusive insights for investors by focusing on the moves of experts: Analysts, Insiders, Bloggers, Hedge Fund Managers and more. See what the experts are saying about your stocks now at TipRanks.com. As of this writing, Harriet Lefton did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Reasons Kraft Heinz Stock Is a Contrarian Buy * 5 Housing Stocks to Buy for Renewed Homebuilder Confidence * 7 of the Best ETFs to Buy for a Rock-Solid Portfolio Compare Brokers The post 7 Strong Buy Stocks the Street Loves appeared first on InvestorPlace.
- Insider Monkey•last month
Did Hedge Funds Drop The Ball On EXACT Sciences Corporation (EXAS) ?
Insider Monkey has processed numerous 13F filings of hedge funds and famous investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and investors' positions as of the end of the fourth quarter. You can find write-ups about an individual hedge fund's trades on numerous financial news websites. […]
- Benzinga•last month
Goldman Adds EXACT Sciences To Americas Conviction List
EXACT Sciences Corporation (NASDAQ: EXAS ) shares have risen over 50 percent year-to-date, and Goldman Sachs sees further upside ahead. The Analyst Patrick Donnelly maintained a Buy rating on Exact Sciences ...
